German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Eli Lilly & Co has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of the medication.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
(LLY) – Analyzing Eli Lilly and Co’s Short Interest
Eli Lilly and Co’s (NYSE:LLY) short percent of float has risen 14.06% since its last report. The company…
What’s Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for relapsed/refractory B-cell malignancies
Spotlight on Eli Lilly and Co: Analyzing the Surge in Options Activity
Deep-pocketed investors have adopted a bullish approach towards Eli Lilly and Co (NYSE:LLY), and it’s something market players…
Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry
In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
JPMorgan’s $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: ‘They’re All The Rage’
JPMorgan's $500M venture capital fund dives into weight-loss craze, eyeing potential market upheaval in pharmaceuticals.
Eli Lilly and Co Stock: A Deep Dive Into Analyst Perspectives (17 Ratings)
Analysts’ ratings for Eli Lilly and Co (NYSE:LLY) over the last quarter vary from bullish to bearish, as…